Department of Psychiatry, UC San Diego School of Medicine, La Jolla, California, USA.
Department of Neuroscience, The Scripps Research Institute, La Jolla, California, USA.
Addict Biol. 2023 Sep;28(9):e13316. doi: 10.1111/adb.13316.
Anxiety is a critical component of the development and maintenance of drug addiction; however, anti-anxiety medications such as benzodiazepines and beta-blockers (β-adrenergic receptor antagonists) are not used for the treatment of substance use disorder, except for the management of acute withdrawal syndrome. Preclinical studies have shown that beta-blockers may reduce stress-induced relapse; however, the effect of beta blockers on the escalation and maintenance of drug intake has not been tested. To address this issue, we chronically administered the β-adrenergic receptor antagonist propranolol during the escalation or maintenance of cocaine intake in a model of extended access (6 h) to cocaine self-administration (0.5 mg/kg). The behavioural specificity of propranolol was tested using a non-drug reward (saccharin). Daily administration of propranolol (15 mg/kg) prevented the development of escalation of cocaine self-administration and partially reversed self-administration after the establishment of escalation of intake. Moreover, propranolol dose-dependently decreased the motivation for cocaine tested under a progressive ratio schedule of reinforcement during the development of escalation and after maintenance. Finally, propranolol administration had no effect on the escalation and maintenance of saccharin self-administration. These results demonstrate that chronic treatment with propranolol provides therapeutic efficacy in reducing cocaine self-administration during the development and after the establishment of escalation of cocaine self-administration in an animal model relevant to cocaine use disorder. These results suggest that beta blockers should be further investigated as a target for medication development for the treatment of cocaine use disorder.
焦虑是药物成瘾发展和维持的关键组成部分;然而,抗焦虑药物如苯二氮䓬类和β-受体阻滞剂(β-肾上腺素能受体拮抗剂)并不用于治疗物质使用障碍,除了急性戒断综合征的管理。临床前研究表明,β-受体阻滞剂可能减少应激诱导的复吸;然而,β-受体阻滞剂对药物摄入的升级和维持的影响尚未得到测试。为了解决这个问题,我们在可卡因自我给药的延长访问(6 小时)模型中,在可卡因摄入升级或维持期间,慢性给予β-肾上腺素能受体拮抗剂普萘洛尔。使用非药物奖励(蔗糖)测试了普萘洛尔的行为特异性。普萘洛尔(15mg/kg)的每日给药可防止可卡因自我给药的升级,并在摄入升级建立后部分逆转自我给药。此外,普萘洛尔在升级和维持期间,在递增比率强化方案下测试可卡因的动机时,呈剂量依赖性降低。最后,普萘洛尔给药对蔗糖自我给药的升级和维持没有影响。这些结果表明,在与可卡因使用障碍相关的动物模型中,慢性普萘洛尔治疗可提供减少可卡因自我给药的治疗效果,无论是在发展阶段还是在可卡因自我给药升级建立后。这些结果表明,β-受体阻滞剂应作为药物开发的靶点,进一步研究其治疗可卡因使用障碍的效果。